Osteometer BioTech A/S Announces Allowance of European Patent for Using Synthetic Peptides to Detect N-Telopeptides of Type I Collagen, i.e. the NTX Peptide Fragments.Business Editors BIOWIRE2K COPENHAGEN, Denmark--(BW HealthWire)--June 11, 2001 OSTEOMETER BIOTECH A/S (www.osteobio.com) today announced the allowance on March 21, 2001, of European Patent Appl. No. 94926817.1-2116 covering the use of non-crosslinked, synthetic peptides in immunoassays for detection of N-telopeptides of type I collagen, i.e. the NTX NTX N-Telopeptide Cross-Links (bone resorption marker) NTX Navy Teletypewriter Exchange NTX Nt Extended NTX Network Terminal Accelerator peptide fragments. The patent discloses improved methods for immunological immunologic, immunological emanating from or pertaining to immunology. immunologic competence see immunocompetence. immunologic domains detection of collagen fragments in body fluids comprising the use of any non-crosslinked, synthetic peptide in conjunction with antibodies reactive with selected, synthetic peptides. "The awarding of this patent to us has long been awaited," says Klaus Eldrup-Jorgensen, President & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Osteometer BioTech A/S. "We have previously been awarded, both in the US and elsewhere, patents covering methods for detection of isomerised peptide fragments, e.g. the isomerised telopeptide fragments released during bone resorption Bone resorption is the process by which osteoclasts break down bone and release the minerals, resulting in a transfer of calcium from bone fluid to the blood. The osteoclasts are multi-nucleated cells that contain numerous mitochondria and lysosomes. and measured by the CrossLaps(R) ELISA ELISA (e-li´sah) Enzyme-Linked Immuno-Sorbent Assay; any enzyme immunoassay using an enzyme-labeled immunoreactant and an immunosorbent. ELISA n. , which is marketed by the Company. Now, these rights have been expanded to include the use of regular, non-crosslinked, synthetic peptides mimicking amino acid amino acid (əmē`nō), any one of a class of simple organic compounds containing carbon, hydrogen, oxygen, nitrogen, and in certain cases sulfur. These compounds are the building blocks of proteins. sequences of the N-telopeptides of type I collagen, i.e. the NTX peptide fragments. We strongly believe that this technique is superior compared to the conventional use of human material partly purified from urine, with all the inherited inhomogenicity of native material. Ostex International and its partners have recently initiated marketing of new tests using synthetic NTX peptides, and we are currently evaluating to what extent these products fall under the scope of our patent portfolio in this area." Osteometer BioTech A/S is engaged in the discovery and development of tests to be used in research and management of diseases affecting bone and cartilage cartilage (kär`təlĭj), flexible semiopaque connective tissue without blood vessels or nerve cells. It forms part of the skeletal system in humans and in other vertebrates, and is also known as gristle. . Diseases as osteoporosis and arthritis are characterised by intense pharmaceutical research and the requirements for medical interventions as well as tools for diagnosing and monitoring are high. The Company has already launched several unique products and through alliances with leading diagnostic companies are making these available world wide. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion